MedPath

Repetitive Transcranial Magnetic Stimulation of the Posterior Parietal Cortex in Patients Suffering From Gilles de la Tourette Syndrome

Phase 2
Terminated
Conditions
Tics
Gilles de la Tourette Syndrome
Interventions
Device: Sham rTMS
Device: rTMS
Registration Number
NCT01043549
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Brief Summary

Repetitive transcranial stimulation (rTMS) of the posterior parietal cortex will be applied daily over five days in adult Gilles de la Tourette patients. This approach aims at reducing premonitory sensations believed to induce tics. Patients will be randomized to an active or placebo (sham) group in a crossover design.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
5
Inclusion Criteria
  • Gilles de la Tourette syndrome as defined by DSM IV-R
  • Yale Global Tics Severity Scale (YGTSS) score between 30 et 60
  • Premonitory sensations (" urge to move ")
  • Affiliated to the French social security regime
  • Ability to give informed consent
Exclusion Criteria
  • rTMS : epilepsy, craniotomy scar, pacemaker or neural stimulator, metal implants or foreign bodies, claustrophobia, pregnancy
  • Cognitive impairment (MMS ≤ 24/30)
  • Axis I disorders according to DSM IV-R : psychosis or history of psychosis, bipolar illness, major depressive disorder, addictions (except to nicotine)
  • Impulse control disorders
  • Other chronic debilitating illnesses
  • Unability to give informed consent
  • Participation in another clinical trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Sham stimulationSham rTMS-
StimulationrTMSRepetitive transcranial stimulation of the posterior parietal cortex
Primary Outcome Measures
NameTimeMethod
Yale global tic severity scale (YTGSS)3 months
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Inserm U975

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath